TY - JOUR
T1 - Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV
AU - Ellis, Ronald J.
AU - Diaz, Monica
AU - Sacktor, Ned
AU - Marra, Christina
AU - Collier, Ann C.
AU - Clifford, David B.
AU - Calcutt, Nigel
AU - Fields, Jerel A.
AU - Heaton, Robert K.
AU - Letendre, Scott L.
AU - Franklin, Donald
AU - Best, Brookie
AU - Cookson, Debra
AU - Cushman, Clint
AU - Dawson, Matthew
AU - Fennema Notestine, Christine
AU - Weibel, Sara Gianella
AU - Grant, Igor
AU - Marcotte, Thomas D.
AU - Marquie-Beck, Jennifer
AU - Vaida, Florin
AU - Rogalski, Vincent
AU - Morgello, Susan
AU - Mintz, Letty
AU - McCutchan, J. Allen
AU - Storey, Sher
AU - Gelman, Benjamin
AU - Head, Eleanor
AU - Teshome, Mengesha
N1 - Funding Information:
The CNS HIV Anti-Retroviral Therapy Effects Research was supported by awards N01 MH22005, HHSN271201000036C, HHSN271201000030C and R01 MH107345 from the National Institutes of Health. The CNS HIV Anti-Retroviral Therapy Effects Research was supported by awards N01 MH22005, HHSN271201000036C, HHSN271201000030C and R01 MH107345 from the National Institutes of Health. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with Johns Hopkins University; the Icahn School of Medicine at Mount Sinai; University of California, San Diego; University of Texas, Galveston; University of Washington, Seattle; Washington University, St. Louis; and is headquartered at the University of California, San Diego and includes: Directors: Robert K. Heaton, Ph.D., Scott L. Letendre, M.D.; Center Manager: Donald Franklin, Jr.; Coordinating Center: Brookie Best, Pharm.D., Debra Cookson, M.P.H, Clint Cushman, Matthew Dawson, Ronald J. Ellis, M.D., Ph.D., Christine Fennema Notestine, Ph.D., Sara Gianella Weibel, M.D., Igor Grant, M.D., Thomas D. Marcotte, Ph.D. Jennifer Marquie-Beck, M.P.H., Florin Vaida, Ph.D.; Johns Hopkins University Site: Ned Sacktor, M.D. (P.I.), Vincent Rogalski; Icahn School of Medicine at Mount Sinai Site: Susan Morgello, M.D. (P.I.), Letty Mintz, N.P.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.); University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Sher Storey, PA-C.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.D. (P.I.), Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Mengesha Teshome, M.D. The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government.
Funding Information:
The CNS HIV Anti‐Retroviral Therapy Effects Research was supported by awards N01 MH22005, HHSN271201000036C, HHSN271201000030C and R01 MH107345 from the National Institutes of Health.
Publisher Copyright:
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Objective: Distal sensory polyneuropathy (DSP) and neuropathic pain are important clinical concerns in virally suppressed people with HIV. We determined how these conditions evolved, what factors influenced their evolution, and their clinical impact. Methods: Ambulatory, community-dwelling HIV seropositive individuals were recruited at six research centers. Clinical evaluations at baseline and 12 years later determined neuropathy signs and distal neuropathic pain (DNP). Additional assessments measured activities of daily living and quality of life (QOL). Factors potentially associated with DSP and DNP progression included disease severity, treatment, demographics, and co-morbidities. Adjusted odds ratios were calculated for follow-up neuropathy outcomes. Results: Of 254 participants, 21.3% were women, 57.5% were non-white. Mean baseline age was 43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173 participants initially pain-free, 42 (24.3%) had incident neuropathic pain. Baseline risk factors for incident pain included unemployment (OR [95% CI], 5.86 [1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per 10-units). Participants with neuropathic pain at follow-up had significantly worse QOL and greater dependence in activities of daily living than those who remained pain-free. Interpretation: HIV DSP and neuropathic pain increased in prevalence and severity over 12 years despite high rates of viral suppression. The high burden of neuropathy included disability and poor life quality. However, substantial numbers remained pain-free despite clear evidence of neuropathy on exam. Protective factors included being employed and having a lower BMI. Implications for clinical practice include promotion of lifestyle changes affecting reversible risk factors.
AB - Objective: Distal sensory polyneuropathy (DSP) and neuropathic pain are important clinical concerns in virally suppressed people with HIV. We determined how these conditions evolved, what factors influenced their evolution, and their clinical impact. Methods: Ambulatory, community-dwelling HIV seropositive individuals were recruited at six research centers. Clinical evaluations at baseline and 12 years later determined neuropathy signs and distal neuropathic pain (DNP). Additional assessments measured activities of daily living and quality of life (QOL). Factors potentially associated with DSP and DNP progression included disease severity, treatment, demographics, and co-morbidities. Adjusted odds ratios were calculated for follow-up neuropathy outcomes. Results: Of 254 participants, 21.3% were women, 57.5% were non-white. Mean baseline age was 43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173 participants initially pain-free, 42 (24.3%) had incident neuropathic pain. Baseline risk factors for incident pain included unemployment (OR [95% CI], 5.86 [1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per 10-units). Participants with neuropathic pain at follow-up had significantly worse QOL and greater dependence in activities of daily living than those who remained pain-free. Interpretation: HIV DSP and neuropathic pain increased in prevalence and severity over 12 years despite high rates of viral suppression. The high burden of neuropathy included disability and poor life quality. However, substantial numbers remained pain-free despite clear evidence of neuropathy on exam. Protective factors included being employed and having a lower BMI. Implications for clinical practice include promotion of lifestyle changes affecting reversible risk factors.
UR - http://www.scopus.com/inward/record.url?scp=85087407081&partnerID=8YFLogxK
U2 - 10.1002/acn3.51097
DO - 10.1002/acn3.51097
M3 - Article
C2 - 32619341
AN - SCOPUS:85087407081
SN - 2328-9503
VL - 7
SP - 1166
EP - 1173
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 7
ER -